Healthcare AI company ConnectedLife revealed on Tuesday that it plans to advance Parkinson's Disease diagnosis and treatment via safe sharing of patient-generated data in partnership with Ocean Protocol, a decentralised data exchange protocol.
Through clinical trials with the National Neuroscience Institute in Singapore and other research partners in Germany and Turkey, ConnectedLife gathers tens of thousands of minutes free-living motion data from Parkinson's Disease patients to monitor motor the symptoms by combining Internet of Things (IoT) and deep learning technology.
Headquartered in Singapore, the company added that the raw data is then processed continuously over time to develop a predictive model to objectively detect Parkinson's Disease motor symptoms. Ocean Protocol provides the technology for the patient-generated data to be shared in a privacy-preserving and secure manner.
In conjunction, ConnectedLife said its high-resolution motion and biomedical data provides objective symptom measures and is shared via Ocean Protocol with healthcare professionals to help prescribe personalised treatments, so patients can be maintained in the optimal therapeutic range to prevent unwanted side effects and symptom fluctuations, significantly improving their quality of life. In addition, machine learning is used to facilitate the development of technology for early diagnosis.
More than 10 million people worldwide are living with Parkinson's Disease, but there is no cure and current therapies are limited to addressing symptoms, most notably the loss of spontaneous movement.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval